Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin-Va (MYO5A) is an unconventional myosin, a motor protein that uses ATP hydrolysis to move along actin filaments and to transport intracellular cargo. It is particularly important in melanocytes for transferring melanosomes (pigment-containing organelles) to the cell periphery, and in neurons, where it traffics organelles and proteins and supports exocytosis. MYO5A interacts with Rab27A and melanophilin to form complexes critical for melanosome transport. It can also bind microtubules, acting as a bridge between actin and microtubule cytoskeletons, and may help cross-link and coordinate these systems[1][3][4][5]. Defects or loss-of-function mutations in MYO5A underlie Griscelli syndrome type 1, a rare autosomal recessive disorder characterized by pigment dilution and severe neurological symptoms. Although MYO5A plays important physiological roles, it has not been established as a direct therapeutic drug target, nor are there known drugs designed to modulate its activity[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myosin-Va (MYO5A).